Logo.jpg
ProPhase Labs’ Cancer Therapeutic, Linebacker-1, pre-clinical studies with Dana Farber/Harvard Cancer Institute demonstrate impressive utility and move into next phase of testing
June 01, 2023 08:30 ET | ProPhase Labs, Inc.
Linebacker fully inhibited lung cancer cell growth and significantly limited colon cancer cell growth in two separate clonogenic models Development ahead of schedule with mice studies well underway...
AroCell AB (publ) In
AroCell AB (publ) Interim Report January 1st to June 30th 2019
August 21, 2019 02:00 ET | AroCell AB
Word from the CEO “It is with pleasure that I can say that the second quarter of 2019 became one of the most exciting and active quarters in AroCell's history. The goal of establishing AroCell as...
AroCell AB (publ) De
AroCell AB (publ) Delårsrapport 1 januari – 30 juni 2019
August 21, 2019 02:00 ET | AroCell AB
VD-ORD ”Det är med glädje som jag kan konstatera att det andra kvartalet 2019 blev ett av det mest spännande och aktiva kvartal i AroCells historia. Målet att etablera AroCell som den givne partnern...
AroCell enters a col
AroCell enters a collaboration with Dana Farber Cancer Institute
August 01, 2019 11:15 ET | AroCell AB
Today AroCell announces a collaboration with Dana Faber Cancer Institute to evaluate AroCell’s TK 210 ELISA assay on CDK4/6 inhibitor treated patients. The aim of the study is to examine concordance...
AroCell inleder ett
AroCell inleder ett samarbete med Dana Farber Cancer Institute
August 01, 2019 11:15 ET | AroCell AB
Idag tillkännager AroCell ett samarbete med Dana Faber Cancer Institute för att utvärdera AroCell TK 210 ELISA på patienter behandlade med CDK4/6-hämmare. Syftet med studien är att undersöka...
desc
New Cancer Research Set to Improve Patient Care
May 02, 2014 12:04 ET | Colon Cancer Alliance
WASHINGTON, May 2, 2014 (GLOBE NEWSWIRE) -- In conjunction with the kickoff of National Cancer Research Month, the Colon Cancer Alliance has announced its first-ever recipient of the Blue Hope...